NCT01638533
Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction treatment 1 active_not_recruiting NCT01364051
Cediranib Maleate and Selumetinib Sulfate in Treating Patients With Solid Malignancies treatment 1 active_not_recruiting NCT01940809
Ipilimumab With or Without Dabrafenib, Trametinib, and/or Nivolumab in Treating Patients With Melanoma That Is Metastatic or Cannot Be Removed by Surgery treatment 1 terminated NCT03276832
Imiquimod and Pembrolizumab in Treating Patients With Stage IIIB-IV Melanoma treatment 0 active_not_recruiting NCT03384836
Propranolol Hydrochloride and Pembrolizumab in Treating Patients With Stage IIIC-IV Melanoma That Cannot Be Removed by Surgery treatment 1 / 2 recruiting NCT01708941
Ipilimumab With or Without High-Dose Recombinant Interferon Alfa-2b in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery treatment 2 active_not_recruiting NCT03326258
Glembatumumab Vedotin, Nivolumab, and Ipilimumab in Treating Patients With Advanced Metastatic Solid Tumors That Cannot Be Removed by Surgery treatment 1 / 2 withdrawn NCT02304458
Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas treatment 1 / 2 completed NCT02097225
Onalespib, Dabrafenib, and Trametinib in Treating Patients With BRAF-Mutant Melanoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery treatment 1 unknown_status NCT02581930
Ibrutinib in Treating Patients With Refractory Metastatic Cutaneous Melanoma treatment 2 active_not_recruiting NCT01807182
Tumor-Infiltrating Lymphocytes After Combination Chemotherapy in Treating Patients With Metastatic Melanoma treatment 2 completed NCT01902173
Uprosertib, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer treatment 1 / 2 active_not_recruiting NCT02500576
Pembrolizumab, Standard Chemotherapy, Tumor Infiltrating Lymphocytes, and High- or Low-Dose Aldesleukin in Treating Patients With Metastatic Melanoma treatment 2 completed NCT01727076
Recombinant Interleukin-15 in Treating Patients With Advanced Melanoma, Kidney Cancer, Non-small Cell Lung Cancer, or Squamous Cell Head and Neck Cancer treatment 1 completed NCT01955460
Genetically Modified T-Cells Followed by Aldesleukin in Treating Patients With Stage III-IV Melanoma treatment 1 active_not_recruiting NCT03325101
Dendritic Cell Therapy After Cryosurgery in Combination With Pembrolizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Remove by Surgery treatment 1 / 2 completed NCT01989572
Sargramostim, Vaccine Therapy, or Sargramostim and Vaccine Therapy in Preventing Disease Recurrence in Patients With Melanoma That Has Been Removed By Surgery prevention 3 completed NCT01134614
Ipilimumab With or Without Sargramostim in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery treatment 2 active_not_recruiting NCT01258855
Aldesleukin With or Without Ziv-Aflibercept in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery treatment 2 completed NCT01274338
Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery treatment 3 active_not_recruiting NCT01480154
Akt Inhibitor MK2206 and Hydroxychloroquine in Treating Patients With Advanced Solid Tumors, Melanoma, Prostate or Kidney Cancer treatment 1 active_not_recruiting NCT03425461
Anti-SEMA4D Monoclonal Antibody VX15/2503 With Nivolumab or Ipilimumab in Treating Patients With Stage III or IV Melanoma treatment 1 terminated NCT02339571
A Phase II/III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients With Advanced Melanoma treatment 2 / 3 recruiting NCT00937937
Dinaciclib in Treating Patients With Stage IV Melanoma treatment 2 active_not_recruiting NCT02910700
Nivolumab With Trametinib and Dabrafenib, or Encorafenib and Binimetinib in Treating Patients With BRAF Mutated Metastatic or Unresectable Stage III-IV Melanoma treatment 2 active_not_recruiting NCT02129075
A Vaccine (CDX-1401) With or Without a Biologic Drug (CDX-301) for the Treatment of Patients With Stage IIB-IV Melanoma treatment 2 completed NCT00861913
Pazopanib Hydrochloride in Treating Patients With Metastatic Melanoma That Cannot be Removed by Surgery treatment 2 completed NCT01303341
Riluzole and Sorafenib Tosylate in Treating Patients With Advanced Solid Tumors or Melanoma treatment 1 active_not_recruiting NCT02965716
Talimogene Laherparepvec and Pembrolizumab in Treating Patients With Stage III-IV Melanoma treatment 2 active_not_recruiting NCT02027935
CD8+ Antigen-Specific T Cells, Cyclophosphamide, Aldesleukin, and Ipilimumab in Treating Patients With Metastatic Melanoma treatment 2 completed NCT02519322
Neoadjuvant and Adjuvant Checkpoint Blockade treatment 2 completed NCT01740557
Genetically Modified Therapeutic Autologous Lymphocytes Followed by Aldesleukin in Treating Patients With Stage III or Metastatic Melanoma treatment 1 / 2 completed NCT02158520
Nab-Paclitaxel and Bevacizumab or Ipilimumab as First-Line Therapy in Treating Patients With Stage IV Melanoma That Cannot Be Removed by Surgery treatment 2 completed NCT03021460
Pembrolizumab and Ibrutinib in Treating Patients with Stage III-IV Melanoma That Cannot Be Removed by Surgery No drug interventions treatment 1 active_not_recruiting NCT03050060
Image Guided Hypofractionated Radiation Therapy, Nelfinavir Mesylate, Pembrolizumab, Nivolumab and Atezolizumab in Treating Patients With Advanced Melanoma, Lung, or Kidney Cancer treatment 2 terminated NCT01590069
Aerosolized Aldesleukin in Treating Patients With Lung Metastases treatment 1 active_not_recruiting NCT02196181
Dabrafenib and Trametinib for the Treatment of Patients With Stage III-IV BRAF Mutant Melanoma That Cannot Be Removed by Surgery treatment 2 active_not_recruiting NCT01950390
Ipilimumab With or Without Bevacizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery treatment 2 active_not_recruiting NCT03427398
Ibrutinib in Treating Patients With Refractory Metastatic Cutaneous Melanoma treatment 2 active_not_recruiting